Staffan Hägg

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4855392/publications.pdf

Version: 2024-02-01

85 papers

4,152 citations

39 h-index 62 g-index

85 all docs

85 docs citations

85 times ranked 3888 citing authors

#	Article	IF	CITATIONS
1	Incidence of fatal adverse drug reactions: a population based study. British Journal of Clinical Pharmacology, 2008, 65, 573-579.	1.1	265
2	Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions–ÂA Meta-Analysis. PLoS ONE, 2012, 7, e33236.	1.1	224
3	Prevalence of Diabetes and Impaired Glucose Tolerance in Patients Treated With Clozapine Compared With Patients Treated With Conventional Depot Neuroleptic Medications. Journal of Clinical Psychiatry, 1998, 59, 294-299.	1.1	189
4	Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiology and Drug Safety, 2002, 11, 65-72.	0.9	168
5	Association of venous thromboembolism and clozapine. Lancet, The, 2000, 355, 1155-1156.	6.3	152
6	Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. British Journal of Clinical Pharmacology, 2001, 51, 169-173.	1.1	128
7	Myocarditis Related to Clozapine Treatment. Journal of Clinical Psychopharmacology, 2001, 21, 382-388.	0.7	120
8	High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. International Clinical Psychopharmacology, 2006, 21, 93-98.	0.9	116
9	Antipsychotic-Induced Venous Thromboembolism. CNS Drugs, 2002, 16, 765-776.	2.7	106
10	Glucose Intolerance with Atypical Antipsychotics. Drug Safety, 2002, 25, 1107-1116.	1.4	104
11	Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. European Journal of Clinical Pharmacology, 2015, 71, 1525-1533.	0.8	104
12	Nonâ€linear fluvoxamine disposition. British Journal of Clinical Pharmacology, 1998, 45, 257-263.	1.1	97
13	Fatal unintentional intoxications with tramadol during 1995–2005. Forensic Science International, 2007, 173, 107-111.	1.3	81
14	Analgesics and Breast-Feeding. Paediatric Drugs, 2000, 2, 223-238.	1.3	79
15	Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opinion on Drug Safety, 2009, 8, 537-547.	1.0	76
16	IN VITRO EFFECTS OF ANTIPSYCHOTICS ON HUMAN PLATELET ADHESION AND AGGREGATION AND PLASMA COAGULATION. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 775-780.	0.9	75
17	Excretion of Paroxetine Into Breast Milk. Journal of Clinical Psychiatry, 1999, 60, 519-523.	1.1	73
18	Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. European Journal of Clinical Pharmacology, 1997, 52, 129-133.	0.8	70

#	Article	IF	CITATIONS
19	Drugâ€induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety, 2008, 17, 587-592.	0.9	70
20	Anticonvulsant Use During Lactation. Drug Safety, 2000, 22, 425-440.	1.4	66
21	Associations Between Venous Thromboembolism andÂAntipsychotics. Drug Safety, 2008, 31, 685-694.	1.4	66
22	Leptin Concentrations Are Increased in Subjects Treated With Clozapine or Conventional Antipsychotics. Journal of Clinical Psychiatry, 2001, 62, 843-848.	1.1	66
23	Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiology and Drug Safety, 2009, 18, 1192-1198.	0.9	63
24	Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. British Journal of Clinical Pharmacology, 2000, 49, 59-63.	1.1	60
25	Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiology and Drug Safety, 2009, 18, 1039-1047.	0.9	60
26	Prevalence, nature and potential preventability of adverse drug events – a populationâ€based medical record study of 4970 adults. British Journal of Clinical Pharmacology, 2014, 78, 170-183.	1.1	58
27	Effects of Cocoa Extract and Dark Chocolate on Angiotensin-converting Enzyme and Nitric Oxide in Human Endothelial Cells and Healthy Volunteers–A Nutrigenomics Perspective. Journal of Cardiovascular Pharmacology, 2011, 57, 44-50.	0.8	55
28	The major fluvoxamine metabolite in urine is formed by CYP2D6. European Journal of Clinical Pharmacology, 2001, 57, 653-658.	0.8	51
29	Economic Impact of Adverse Drug Events – A Retrospective Population-Based Cohort Study of 4970 Adults. PLoS ONE, 2014, 9, e92061.	1.1	50
30	Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction. British Journal of Clinical Pharmacology, 2009, 68, 427-434.	1.1	48
31	Venous Thromboembolism During Treatment with Antipsychotics: A Review of Current Evidence. CNS Drugs, 2018, 32, 47-64.	2.7	48
32	Current Evidence on Abuse and Misuse of Gabapentinoids. Drug Safety, 2020, 43, 1235-1254.	1.4	48
33	Venous Thromboembolism in Recipients of Antipsychotics. CNS Drugs, 2012, 26, 649-662.	2.7	47
34	Absence of interaction between erythromycin and a single dose of clozapine. European Journal of Clinical Pharmacology, 1999, 55, 221-226.	0.8	46
35	Adherence to Antihypertensive Therapy and Elevated Blood Pressure: Should We Consider the Use of Multiple Medications?. PLoS ONE, 2015, 10, e0137451.	1.1	45
36	Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 83, 674-681.	1.3	44

#	Article	IF	CITATIONS
37	Methods for Assessing the Preventability of Adverse Drug Events. Drug Safety, 2012, 35, 105-126.	1.4	43
38	Effects of green tea, black tea and Rooibos tea on angiotensin-converting enzyme and nitric oxide in healthy volunteers. Public Health Nutrition, 2010, 13, 730.	1.1	42
39	Utilization pattern of metamizole in northern Sweden and risk estimates of agranulocytosis. Pharmacoepidemiology and Drug Safety, 2002, 11, 239-245.	0.9	41
40	Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. International Clinical Psychopharmacology, 2003, 18, 173-174.	0.9	41
41	In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacological Reports, 2012, 64, 979-983.	1.5	39
42	Excretion of Psychotropic Drugs into Breast Milk. CNS Drugs, 1998, 9, 111-134.	2.7	37
43	Prevalence and Perceived Preventability of Self-Reported Adverse Drug Events – A Population-Based Survey of 7099 Adults. PLoS ONE, 2013, 8, e73166.	1.1	37
44	Excretion of fluvoxamine into breast milk. British Journal of Clinical Pharmacology, 2000, 49, 286-288.	1.1	36
45	Urinary Detection Times and Metabolite/Parent Compound Ratios After a Single Dose of Buprenorphine. Journal of Analytical Toxicology, 2008, 32, 586-593.	1.7	35
46	Antipsychotics and risk of venous thromboembolism: A population-based case-control study. Clinical Epidemiology, 2009, 1, 19.	1.5	34
47	Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. European Journal of Clinical Pharmacology, 2000, 56, 699-703.	0.8	32
48	Antipsychotics associated with pulmonary embolism in a Swedish medicolegal autopsy series. International Clinical Psychopharmacology, 2008, 23, 263-268.	0.9	31
49	Repeated Episodes of Hypothermia in a Subject Treated With Haloperidol, Levomepromazine, Olanzapine, and Thioridazine. Journal of Clinical Psychopharmacology, 2001, 21, 113-115.	0.7	30
50	Cerebral haemorrhage induced by warfarinâ€"the influence of drugâ€"drug interactions. Pharmacoepidemiology and Drug Safety, 2007, 16, 309-315.	0.9	30
51	Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden. Pharmacoepidemiology and Drug Safety, 2007, 16, 173-180.	0.9	29
52	Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance. European Journal of Clinical Pharmacology, 1999, 54, 943-946.	0.8	25
53	Olanzapine and venous thromboembolism. International Clinical Psychopharmacology, 2003, 18, 299-300.	0.9	23
54	Fatal drug poisonings in a Swedish general population. BMC Clinical Pharmacology, 2009, 9, 7.	2.5	22

#	Article	IF	CITATIONS
55	Impact of information letters on the reporting rate of adverse drug reactions and the quality of the reports: a randomized controlled study. BMC Clinical Pharmacology, 2011, 11, 14.	2.5	22
56	A Fatal Outcome After Unintentional Overdosing of Rivastigmine Patches. Current Drug Safety, 2012, 7, 30-32.	0.3	21
57	Clozapine and pulmonary embolism. Acta Psychiatrica Scandinavica, 2003, 108, 76-77.	2.2	20
58	Preventable drug related mortality in a Swedish population. Pharmacoepidemiology and Drug Safety, 2010, 19, 211-215.	0.9	20
59	Prolonged Sedation and Slowly Decreasing Clozapine Serum Concentrations After an Overdose. Journal of Clinical Psychopharmacology, 1999, 19, 282-284.	0.7	17
60	Enhanced platelet serotonin 5-HT2A receptor binding in anorexia nervosa and bulimia nervosa. European Neuropsychopharmacology, 1999, 9, 469-473.	0.3	16
61	Non-prescribed use of psychoactive prescription drugs among drug-impaired drivers in Sweden. Drug and Alcohol Dependence, 2016, 161, 77-85.	1.6	16
62	Therapeutic Drug Monitoring of Ziprasidone in a Clinical Treatment Setting. Therapeutic Drug Monitoring, 2008, 30, 682-688.	1.0	15
63	A prospective analysis of the preventability of adverse drug reactions reported in Sweden. European Journal of Clinical Pharmacology, 2012, 68, 1183-1189.	0.8	15
64	Serum Levels of Olanzapine in a Non-Fatal Overdose. Journal of Analytical Toxicology, 2007, 31, 119-121.	1.7	14
65	The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting. European Journal of Clinical Pharmacology, 2015, 71, 631-636.	0.8	14
66	ABCB1 gene polymorphisms are associated with suicide in forensic autopsies. Pharmacogenetics and Genomics, 2013, 23, 463-469.	0.7	13
67	The understanding of core pharmacological concepts among health care students in their final semester. BMC Medical Education, 2015, 15, 235.	1.0	12
68	Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors. International Clinical Psychopharmacology, 2003, 18, 157-161.	0.9	11
69	Modelling drug-related morbidity in Sweden using an expert panel of pharmacists'. International Journal of Clinical Pharmacy, 2012, 34, 538-546.	1.0	10
70	Use of non-benzodiazepine hypnotics is associated with falls in nursing home residents: a longitudinal cohort study. Aging Clinical and Experimental Research, 2019, 31, 1087-1095.	1.4	10
71	Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers. Drug, Healthcare and Patient Safety, 2010, 2, 21.	1.0	9
72	Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system. BMC Pharmacology & Expression (2014), 15, 31.	1.0	9

#	Article	IF	CITATIONS
73	Clinical relevance of alerts from a decision support system, PHARAO, for drug safety assessment in the older adults. BMC Geriatrics, 2019, 19, 164.	1.1	8
74	Key Elements in Adverse Drug Interaction Safety Signals. Drug Safety, 2013, 36, 63-70.	1.4	7
75	The Impact of Duration of Treatment on Reported Time-to-Onset in Spontaneous Reporting Systems for Pharmacovigilance. PLoS ONE, 2013, 8, e68938.	1.1	7
76	Modelling drug-related morbidity in Sweden using an expert panel of physicians. European Journal of Clinical Pharmacology, 2012, 68, 1309-1319.	0.8	6
77	Refill adherence and selfâ€reported adverse drug reactions and subâ€therapeutic effects: a populationâ€based study. Pharmacoepidemiology and Drug Safety, 2013, 22, 1317-1325.	0.9	6
78	Comparing Methods for Estimating Direct Costs of Adverse Drug Events. Value in Health, 2017, 20, 1299-1310.	0.1	6
79	Timeâ€toâ€onset in spontaneous reports: the possibility to detect the unexpected. Pharmacoepidemiology and Drug Safety, 2013, 22, 556-557.	0.9	5
80	Zinc Induces a Bell-shaped Proliferative Dose-response Effect in Cultured Smooth Muscle Cells From Benign Prostatic Hyperplasia. Urology, 2015, 85, 704.e15-704.e19.	0.5	4
81	Direct and indirect costs for adverse drug events identified in medical records across care levels, and their distribution among payers. Research in Social and Administrative Pharmacy, 2017, 13, 1151-1158.	1.5	4
82	On the pedagogy of pharmacological communication: a study of final semester health science students. BMC Medical Education, 2015, 15, 186.	1.0	3
83	Sudden Cardiac Death in Users of Second-Generation Antipsychotics. Journal of Clinical Psychiatry, 2009, 70, 1725-1726.	1.1	3
84	Therapeutic approaches to bulimia nervosa. Expert Opinion on Therapeutic Patents, 2001, 11, 463-477.	2.4	2
85	The Cone Evasion Walk test: Reliability and validity in acute stroke. Physiotherapy Research International, 2019, 24, e1744.	0.7	2